Disclaimer:All content on this platform is sourced from the internet and is provided for informational purposes only. None of the content represents the views of this site, nor does it constitute investment advice. Please exercise caution when investing.

Faster global financial news!

Gilead Sciences (01672.HK): The U.S. FDA has approved the Investigational New Drug (IND) application for a 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist, in diabetic patients.

04/01/2026 16:03 UTC
Svmuu Editorial Team
Share
Complaint Report
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
i
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
#Hong Kong and U.S. Stocks
prev Previous: Maduro's Arrest in the U.S. Shocks Markets; Precious Metal Prices Rise on Safe-Haven Demand | Next: Both WTI and Brent crude oil erased early losses of more than 1% to turn higher, currently trading at $57.40 per barrel and $60.71 per barrel, respectively. next
Current Location: Home > Gilead Sciences (01672.HK): The U.S. FDA has approved the Investigational New Drug (IND) application for a 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist, in diabetic patients.

24H Trending

Markets Today

BTCBitcoin
$75,878.99 -0.15%
ETHEthereum
$2,237.77 -0.48%
USDTTether USDt
$1.00 +0.01%
BNBBNB
$696.65 +0.23%
SP
S&P 500 IndexSPX
7,376.86 +0.31%
XA
GoldXAU
$4,066.07 +0.00%
DX
DXY (US Dollar Index)DXY
102.30 +0.74%
View Full Market Data →
recommend

Recommended Reading

Hot Topics

#digital currency #Macro #U.S. stocks #Stocks #Geopolitics #Hong Kong and U.S. Stocks #Foreign Exchange #Commodities #Bitcoin #Binance #Cryptocurrency #Artificial Intelligence #Iran #Ethereum #Bonds #United States

Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.

Coming Soon!
Scan to Download App